(Q38783064)

6 September 2017

Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia (English)

1 reference

6 September 2017

1

Peter H Wiernik

1 reference

PubMed ID

26998706

6 September 2017

language of work or name

English

0 references

publication date

21 March 2016

1 reference

Expert Opinion on Investigational Drugs

6 September 2017

1 reference

6 September 2017

25

1 reference

6 September 2017

6

1 reference

6 September 2017

729-734

1 reference

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure

6 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Ofatumumab for the treatment of chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US i

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Antitumor effects of flavopiridol on human uterine leiomyoma in vitro and in a xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Cyclin-dependent kinase inhibition by flavoalkaloids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Emerging drug profile: cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Structural, conformational and thermodynamic aspects of groove-directed-intercalation of flavopiridol into DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

The binding of flavopiridol to blood serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

A novel liposomal formulation of flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1169273

10.1517/13543784.2016.1169273

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

26998706